98 related articles for article (PubMed ID: 7565454)
1. Influence of serum phosphate on the efficacy of oral 1,25-dihydroxyvitamin D3 pulse therapy.
Shoji S; Nishizawa Y; Tabata T; Emoto M; Morita A; Goto H; Ishimaura E; Inoue T; Inaba M; Miki T
Miner Electrolyte Metab; 1995; 21(1-3):223-8. PubMed ID: 7565454
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
[TBL] [Abstract][Full Text] [Related]
4. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
Liou HH; Chiang SS; Huang TP; Shieh SD; Akmal M
Miner Electrolyte Metab; 1994; 20(3):97-102. PubMed ID: 7816008
[TBL] [Abstract][Full Text] [Related]
5. Oral 1,25(OH)2D3 pulse therapy for the treatment of secondary hyperparathyroidism.
Takahashi S; Okada K; Kinosita Y; Yanai M; Kuno T; Nagura Y
Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):377-82. PubMed ID: 8341016
[TBL] [Abstract][Full Text] [Related]
6. [The oral 1-25 dihydroxyvitamin D3 pulse therapy in hemodialysis patients for the early treatment of secondary hyperparathyroidism].
Kawabe M; Shimizu M; Takeuchi M; Matsunobu S; Hayama N; Iino Y; Hara K; Terashi A
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):807-11. PubMed ID: 1479720
[TBL] [Abstract][Full Text] [Related]
7. Absence of effect of 24,25-dihydroxycholecalciferol on serum immunoreactive PTH in patients with persistent hyperparathyroidism after renal transplantation.
Friedlander MA; Horst RL; Hawker CD
Clin Nephrol; 1984 Oct; 22(4):206-10. PubMed ID: 6391769
[TBL] [Abstract][Full Text] [Related]
8. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
[TBL] [Abstract][Full Text] [Related]
9. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
Tsukamoto Y; Nomura M; Takahashi Y; Takagi Y; Yoshida A; Nagaoka T; Togashi K; Kikawada R; Marumo F
Nephron; 1991; 57(1):23-8. PubMed ID: 2046811
[TBL] [Abstract][Full Text] [Related]
10. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
Peng SJ; Yang CS; Ferng SH; Chen LY
Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
[TBL] [Abstract][Full Text] [Related]
11. High-dose oral calcitriol and zero calcium peritoneal solutions in CAPD patients with refractory secondary hyperparathyroidism.
Malberti F; Scanziani R; Corradi B; Dozio B; Bonforte G; Imbasciati E; Surian M
Nephrol Dial Transplant; 1994; 9(12):1813-5. PubMed ID: 7708273
[TBL] [Abstract][Full Text] [Related]
12. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure.
Panichi V; Andreini B; De Pietro S; Migliori M; Taccola D; Giovannini L; Ferdeghini M; Palla R
Clin Nephrol; 1998 Apr; 49(4):245-50. PubMed ID: 9582556
[TBL] [Abstract][Full Text] [Related]
13. [Pulsed doses of calcitriol in the treatment of secondary hyperparathyroidism in patients on hemodialysis].
Sotorník I; Petrásek R; Schück O; Adamec M; Smrcková I; Tocík J
Vnitr Lek; 1997 Sep; 43(9):584-91. PubMed ID: 9750467
[TBL] [Abstract][Full Text] [Related]
14. Effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on tubular handling of phosphate in hypophosphatemic rickets.
Alon U; Chan JC
J Clin Endocrinol Metab; 1984 Apr; 58(4):671-5. PubMed ID: 6546575
[TBL] [Abstract][Full Text] [Related]
15. [Low dosage intravenous calcitriol bolus therapy in chronic hemodialysis patients].
Neyer U; Wöss E; Drexel H
Acta Med Austriaca; 1994; 21(5):129-32. PubMed ID: 7709710
[TBL] [Abstract][Full Text] [Related]
16. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
17. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
18. Calcitriol in the management of secondary hyperparathyroidism of renal failure.
Daisley-Kydd RE; Mason NA
Pharmacotherapy; 1996; 16(4):619-30. PubMed ID: 8840368
[TBL] [Abstract][Full Text] [Related]
19. [Research on the treatment of secondary hyperparathyroidism as a complication of chronic renal failure].
Sugimura T
Nihon Jinzo Gakkai Shi; 1991 Nov; 33(11):1119-34. PubMed ID: 1808363
[TBL] [Abstract][Full Text] [Related]
20. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism.
Caravaca F; Cubero JJ; Jimenez F; López JM; Aparicio A; Cid MC; Pizarro JL; Liso J; Santos I
Nephrol Dial Transplant; 1995; 10(5):665-70. PubMed ID: 7566580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
